摘要:
The invention provides methods for treating inflammatory diseases (e.g., chronic inflammatory diseases) comprising administering an antagonist of Tumor Necrosis Factor Receptor 1. The invention also provides antagonists of Tumor Necrosis Factor Receptor 1, such as ligands that contain an immunoglobulin single variable domain or domain antibody (dAb) monomer that binds Tumor Necrosis Factor Receptor 1, and methods of using the ligands. Also provided are nucleic acids encoding the ligands, recombinant host cells and methods for preparing the ligands.
摘要:
The present invention relates to a simple method for generating antibody-based structures suitable for in vivo use. In particular, the invention relates to a method for the generation of antibody-based structures suitable for in vivo use comprising the steps of: (a) selecting an antibody single variable domain having an epitope binding specificity; and (b) attaching the single domain of step (a) to an effector group. Uses of molecules generated using the method of the Invention are also described.
摘要:
The invention provides a dual-specific ligand comprising a first and second single variable domain, each having binding specificity for a antigenic target. The invention also provides for a single variable domain monomer ligand that specifically binds to an antigenic target.
摘要:
The present invention provides a domain antibody construct which binds to human TNF-α, the construct comprising: (a) a domain antibody (dAb) which binds to human TNF-α; (b) a modified hinge region sequence; (c) a human or primate heavy chain constant region sequence having a truncated CH1 domain of not more than 20 residues, wherein said modified hinge region sequence contains either a deletion or a single amino acid substitution of at least one cysteine residue which normally facilitates disulfide bond formation between heavy and light antibody chains.
摘要翻译:本发明提供结合人TNF-α的结构域抗体构建体,所述构建体包含:(a)结合人TNF-α的结构域抗体(dAb); (b)修饰的铰链区序列; (c)具有不超过20个残基的截短C 1 H 1结构域的人或灵长类重链恒定区序列,其中所述修饰的铰链区序列含有缺失或单个氨基酸取代, 至少一个半胱氨酸残基通常促进重和轻抗体链之间的二硫键形成。
摘要:
The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.
摘要:
Disclosed are ligands comprising a first polypeptide domain having a binding site with binding specificity for a first cell surface target and a second polypeptide domain having a binding site for a second cell surface target, wherein each target are different and on the same cell. In some embodiments, the ligands described further comprise a toxin. In other embodiments, the ligands further comprise half-life extending moieties. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.
摘要:
Disclosed are ligands that have binding specificity for interleukin-4 (IL-4), for interleukin-13 (IL-13), or for IL-4 and IL-13. Also disclosed are methods of using these ligands. In particular, the use of these ligands for treating allergic asthma is described.
摘要:
A curable amine flux composition is provided, comprising, as initial components: a resin component having at least two oxirane groups per molecule; an amine fluxing agent represented by formula I: wherein R1, R2, R3 and R4 are independently selected from a hydrogen, a substituted C1-80 alkyl group, an unsubstituted C1-80 alkyl group, a substituted C7-80 arylalkyl group and an unsubstituted C7-80 arylalkyl group; wherein R7 and R8 are independently selected from a C1-20 alkyl group, a substituted C1-20 alkyl group, a C6-20 aryl group and a substituted C6-20 aryl group or wherein R7 and R8, together with the carbon to which they are attached, form a C3-20 cycloalkyl ring optionally substituted with a C1-6 alkyl group; wherein R10 and R11 are independently selected from a C1-20 alkyl group, a substituted C1-20 alkyl group, a C6-20 aryl group and a substituted C6-20 aryl group or wherein R10 and R11, together with the carbon to which they are attached, form a C3-20 cycloalkyl ring optionally substituted with a C1-6 alkyl group; and, wherein R9 is selected from a hydrogen, a C1-30 alkyl group, a substituted C1-30 alkyl group, a C6-30 aryl group and a substituted C6-30 aryl group; and, optionally, a curing agent. Also provided is a method of soldering an electrical contact using the curable amine flux composition.
摘要:
The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.
摘要:
The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.